Captrust Financial Advisors Sells 12,027 Shares of Genmab A/S (NASDAQ:GMAB)

Captrust Financial Advisors cut its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 26.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 32,823 shares of the company’s stock after selling 12,027 shares during the period. Captrust Financial Advisors’ holdings in Genmab A/S were worth $800,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. DDD Partners LLC purchased a new position in Genmab A/S during the 2nd quarter valued at $8,860,000. Cubist Systematic Strategies LLC boosted its stake in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after purchasing an additional 145,689 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after buying an additional 103,859 shares during the period. Sanctuary Advisors LLC bought a new position in Genmab A/S in the second quarter worth about $1,354,000. Finally, Ingalls & Snyder LLC raised its stake in Genmab A/S by 29.3% in the second quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock worth $5,772,000 after buying an additional 52,117 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on GMAB shares. Morgan Stanley reiterated an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. Truist Financial decreased their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. BMO Capital Markets restated an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, Redburn Atlantic began coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Up 1.4 %

NASDAQ GMAB opened at $22.11 on Tuesday. Genmab A/S has a 12 month low of $20.34 and a 12 month high of $32.88. The stock’s fifty day moving average price is $22.41 and its 200-day moving average price is $25.29. The stock has a market cap of $14.63 billion, a P/E ratio of 21.47, a P/E/G ratio of 0.68 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the company posted $0.47 earnings per share. As a group, analysts forecast that Genmab A/S will post 1.29 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.